Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opportunities to Optimize Cancer Policies Panel Discussion

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Welcome and Introduction to Vi3C

Feb

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opportunities to Optimize Cancer Policies Panel Discussion

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Welcome and Introduction to Vi3C

Topline PFS Results From BREAKWATER in mCRC Newly Announced

Adding Encorafenib and Cetuximab to FOLFIRI Shows Benefit in BRAF-Mutant Colorectal Cancer

Pleurectomy Decortication Safe in Select Patients With Pleural Mesothelioma

Medical Societies Caution Misinformation May Drive Underuse of Lung Cancer Screening

Chemoradiation Plus Atezolizumab in Limited-Stage Small Cell Lung Cancer